カレントテラピー　35-2　サンプル page 19/32

このページは カレントテラピー　35-2　サンプル の電子ブックに掲載されている19ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
カレントテラピー　35-2　サンプル

52 Current Therapy 2017 Vol.35 No.2150PD-1, a novel member of the immunoglobulin gene superfamily,upon programmed cell death. EMBO J 11：3887-3895,19925）Iwai Y, Ishida M, Tanaka Y, et al：Involvement of PD-L1 ontumor cells in the escape from host immune system andtumor immunotherapy by PD-L1 blockade. Proc Natl AcadSci U S A 99：12293-12297, 20026）Okazaki T, Honjo T：PD-1 and PD-1 ligands：from discoveryto clinical application. Int Immunol 19：813-824, 20077）Brahmer JR, Drake CG, Wollner I, et al：Phase I study ofsingle -agent anti -programmed death -1（MDX -1106）inrefractory solid tumors：safety, clinical activity, pharmacodynamics,and immunologic correlates. J Clin Oncol 28：3167-3175, 20108）Hamanishi J, Mandai M, Iwasaki M, et al：Programmed celldeath 1 ligand 1 and tumor-infiltrating CD8＋ T lymphocytesare prognostic factors of human ovarian cancer. ProcNatl Acad Sci U S A 104：3360-3365, 20079）Hamanishi J, Mandai M, Abiko K, et al：The comprehensiveassessment of local immune status of ovarian cancer by theclustering of multiple immune factors. Clin Immunol 141：338-347, 201110）Hamanishi J, Mandai M, Ikeda T, et al：Safety and AntitumorActivity of Anti-PD-1 Antibody, Nivolumab, in PatientsWith Platinum-Resistant Ovarian Cancer. J Clin Oncol 33：4015-4022, 201511）Hamanishi J, Mandai M, Konishi I：Immune checkpoint inhibitionin ovarian cancer. Int Immunol 28：339-348, 201612）Hamanishi J, Murakami R, Mandai M, et al：Specific genesignatures and oligo -clonal expansion of B cell repertoirewith responders of anti -PD -1 antibody（Nivolumab）forovarian cancer；Novel predictive biomarkers. 2016 ASCOAnnual Meeting. J Clin Oncol 34, 2016（suppl；abstr 55131）13）Frenel JS, Tourneau C, O’Neil BH, et al：Pembrolizumab inpatients with advanced cervical squamous cell cancer：Preliminaryresults from the phase Ib KEYNOTE -028 study.2016 ASCO Annual Meeting. J Clin Oncol 34, 2016（suppl；abstr 5515）14）Brahmer JR, Tykodi SS, Chow LQ, et al：Safety and activity ofanti-PD-L1 antibody in patients with advanced cancer. N EnglJ Med 366：2455-2465, 201215）Disis ML, Patel MR, Pant S, et al：Avelumab（MSB0010718C；anti-PD-L1）in patients with recurrent/refractory ovariancancer from the JAVELIN Solid Tumor phase Ib trial：Safetyand clinical activity. 2016 ASCO Annual Meeting. J ClinOncol 34, 2016（suppl；abstr 5533）16）Lee J, Zimmer AD, Lipkowitz S, et al：Phase I study of thePD-L1 inhibitor, durvalumab（MEDI4736；D）in combinationwith a PARP inhibitor, olaparib（O）or a VEGFR inhibitor,cediranib（C）in women’s cancers（NCT02484404）. 2016ASCO Annual Meeting. J Clin Oncol 34, 2016（suppl；abstr3015）17）Gubin MM, Zhang X, Schuster H, et al：Checkpoint blockadecancer immunotherapy targets tumour-specific mutant antigens.Nature 515：577-581, 201418）Hamanishi J, Mandai M, Matsumura N, et al：PD-1/PD-L1blockade in cancer treatment：perspectives and issues. Int JClin Oncol 21：462-473, 201619）Dong ZY, Wu SP, Liao RQ, et al：Potential biomarker forcheckpoint blockade immunotherapy and treatment strategy.Tumour Biol 37：4251-4261, 201620）Strickland KC, Howitt BE, Shukla SA, et al：Association andprognostic significance of BRCA1/2-mutation status withneoantigen load, number of tumor-infiltrating lymphocytesand expression of PD-1/PD-L1 in high grade serous ovariancancer. Oncotarget 7：13587-13598, 2016